期刊文献+

纳米载药系统在肿瘤多药耐药中的应用

The Application of Nanoparticles Drug System in Cancer Multidrug Resistance
原文传递
导出
摘要 当今世界,肿瘤已经成为威胁人类健康的重大疾病。在肿瘤疾病中,化疗可控制肿瘤的生长和转移,增强放疗的疗效,是治疗肿瘤疾病的主要手段之一。而肿瘤多药耐药是影响化疗药物疗效、引起化疗失败的重要原因,影响肿瘤患者的治愈效果,降低生存率。如何提高化疗的疗效,延长肿瘤患者的寿命成为医学界的难题。纳米载药系统是生物医学领域研究的热点,相对于单一药物,纳米载药体现了许多优越性,具有良好的应用前景。纳米级颗粒更有利于药代动力学,这些纳米载药颗粒通过被动和主动的机制表现出在全身血液循环寿命延长,持续的药物释放动力,使其能更好的在肿瘤细胞中积累而发挥作用,提高化疗的疗效。本文综述了肿瘤多药耐药研究中主要的纳米载体以及它们在逆转多药耐药方面的应用,并展望载药系统的有更多更好的发展趋势。 At present, cancer is a serious diease that is threatening the health of human. Chemotherapy has been one of the most treatment method for cancer that can control the growth and transference for cancer, enhance the efficacy of radiotherapy. Cancer multidrug resistance is the important element that influences treatment efficacy for cancer, and is the most important failture reason for treating cancer, influences the efficacy of treating and decreases the survive rate. How to elevate the efficacy of chemotherapy and postpone the life of patient is the challenge for medicine. Nano particle is better beneficial for the pharmacokinetics, those nano particle prolongs lifetime in the blood circulation by active and passive mechanism, extends dynamic of drug release consistently, it can be better for accumulating and developing function, so that it can highlight the efficacy of drug. The nanoparticles drug system is the hot topic in bimedicine, it has much more advantages than single drug. There is a super prospective in medical application. We clarify the major nanocarriers and their applications in multidrug resistance, and the uses in the field of reversion nanoparticle drug, hope that the future developing trend.
出处 《现代生物医学进展》 CAS 2014年第28期5599-5600,5564,共3页 Progress in Modern Biomedicine
关键词 纳米载体 肿瘤 多药耐药 Nanoparticle carrier Tumor Nanoparticle
  • 相关文献

参考文献18

  • 1Assaraf YG. Molecular basis of antifolate resistance [J]. Cancer metastasis reviews, 2007,26( 1 ): 153-181.
  • 2Hu CM. Therapeutic nanoparticles to combat cancer drug resistance [J]. Current drug metabolism, 2009,10(8):836-841.
  • 3周文菁,周望,贾守薇,刘韬,符立梧,吴琳,黄红兵.阿霉素脂质体对克服肿瘤多药耐药的细胞学体外评价[J].中国医院药学杂志,2012,32(17):1349-1352. 被引量:3
  • 4Bayne WF, Mayer L D, Swenson C E. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HC1) liposome injection in the mouse [J]. Journal of pharmaceutical sciences, 2009,98(7):2540-2548.
  • 5Gyulai G. Influence of surface properties of polymeric nanoparticles on their membrane affinity [J]. European Polymer Journal, 2013(in press).
  • 6Duan J.Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly (butyl cyanoacrylate) nanoparticles [J]. International Journal of Pharmaceutics, 2012,426 (1-2): 193-201.
  • 7Muller RH. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant [J]. Pharmaceutical research, 1997,14(4) :458-462.
  • 8Ma P. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia [J]. Journal of biomedical nanotechnology, 2009,5 (2): 151-161.
  • 9Han CY. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells [J]. Carcinogenesis(Oxford), 2008,29(9): 1837-1844.
  • 10Kang KW.Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy [J]. Nanomedicine:Nanotechn-ology, Biology and Medicine, 2010,6(2):210-213.

二级参考文献10

  • 1叶果,柯爱武,李羲.MRK-16修饰阿霉素免疫脂质体逆转肺癌细胞多药耐药研究[J].现代肿瘤医学,2007,15(6):754-757. 被引量:9
  • 2Robert J, Jarry C,Multidrug resistance reversal agents[J]. J Med Chem, 2003,46 (23) :4805-4817.
  • 3Poirier VJ, Thamm DH, Kurzman ID,et al. Liposomeencap- sulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats[J].J Vet Intern Med, 2002, ] 6 (6) : 726-731.
  • 4Fu L, Liang Y, Deng I., et al. Characterization of tetran- drine, a potent inhibitor of P-glyeoprotein-mediated multidrug resistance[J].2004,53(4) :349-356. Li X,Stuekert P,.
  • 5Bosch I, et al. Single-chain antibody-media ted gene delivery into ErbB 2-position human breast cancer cell[J]. Cancer Gene Ther, 2001,8(8) :555 -565.
  • 6Thierry AR,Vige D, Coughlin SS,et al. Modulation of doxo- rubicin resistance in multidrug resistant cells by liposomes[J]. FASEB J, 1993,7 (6) : 572-579.
  • 7Mamasheva, E, ODonnell C, Bandekar A,etal. Heterogene- ous liposome membranes with pH-triggered permeability en hanee the in witro antitumor activity of folate-receptor targeted liposomal doxorubicin[J].Mol Pharm, 2011,8 (6): 2224-2232.
  • 8Kang DI,Kang HK,Gwak HS. I.iposome composition is im portant for retention of liposomal rhodamine in P-glycoprotein overexpressing cancer cells[J]. Drug Deliv, 2009, 16(5): 26l-267.
  • 9Yuan F,Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size[J]. Cancer Res, 1995,55 (17) : 3752-3756.
  • 10颜科,胡春梅,潘黎军,王驰.阿霉素脂质体的制备及对MCF-7/DOX作用的考察[J].重庆医科大学学报,2009,34(3):329-331. 被引量:6

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部